Morphine glucuronidation in preterm neonates, infants and children younger than 3 years

Clinical Pharmacokinetics

Volumn 48, Issue 6, 2009, Pages 371-385

  Knibbe, Catherijne A J ^a,b,c   Krekels, Elke H J ^b,c   Van Den Anker, Johannes N ^c,d   DeJongh, Joost ^b,e   Santen, Gijs W E ^b   Van Dijk, Monique ^c   Simons, Sinno H P ^c   Van Lingen, Richard A ^f   Jacqz Aigrain, Evelyne M ^g   Danhof, Meindert ^b   Tibboel, Dick ^c  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e LAP and P Consultants BV   (Netherlands)

^f ISALA HOSPITAL   (Netherlands)

^g HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE;

AGE DISTRIBUTION; ALLOMETRY; ARTICLE; BIRTH WEIGHT; BODY WEIGHT; CLINICAL TRIAL; COMPUTER PROGRAM; CONTINUOUS INFUSION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG GLUCURONIDATION; FEMALE; HUMAN; INFANT; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEWBORN; PAIN; PERINATAL PERIOD; POPULATION DISTRIBUTION; POPULATION MODEL; PREMATURITY; PRIORITY JOURNAL;

AGE FACTORS; CHILD, PRESCHOOL; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; METABOLIC CLEARANCE RATE; MORPHINE;

EID: 68249144472     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-200948060-00003     Document Type: Article

References (45)

1. Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999; 80 (2): F142-4
2. Danhof M, de Jongh J, de Lange EC, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 2007; 47: 357-400
3. de Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999; 36 (6): 439-52
4. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002; 300 (2): 361-6
5. Coffman BL, Rios GR, King CD, et al. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997; 25 (1): 1-4
6. Allegaert K, Rayyan M, de Hoon J, et al. Contribution of glucuronidation to tramadol disposition in early neonatal life. Basic Clin Pharmacol Toxicol 2006; 98 (1): 110-2
7. Court MH, Krishnaswamy S, Hao Q, et al. Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. DrugMetab Dispos 2003; 31 (9): 1125-33
8. Barbier O, Turgeon D, Girard C, et al. 3′-azido-3′- deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000; 28 (5): 497-502
9. Simons SH, van Dijk M, Van Lingen RA, et al. Routine morphine infusion in preterm newborns who received ventilatory support: a randomized controlled trial. JAMA 2003; 290 (18): 2419-27
10. van Dijk M, Bouwmeester NJ, Duivenvoorden HJ, et al. Efficacy of continuous versus intermittent morphine administration after major surgery in 0-3-year-old infants: a double-blind randomized controlled trial. Pain 2002; 98 (3): 305-13
11. van Dijk M, de Boer JB, Koot HM, et al. The reliability and validity of the COMFORT scale as a postoperative pain instrument in 0 to 3-year-old infants. Pain 2000; 84 (2-3): 367-77
12. Van der Marel CD, Peters JW, Bouwmeester NJ, et al. Rectal acetaminophen does not reduce morphine consumption after major surgery in young infants. Br J Anaesth 2007; 98 (3): 372-9
13. Brendel K, Comets E, Laffont C, et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 2006; 23 (9): 2036-49
14. Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the NPDE add-on package for R. Comput Methods Programs Biomed 2008; 90 (2): 154-66
15. BrendelK,Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46 (3): 221-34
16. Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47 (4): 231-43
17. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 2002; 41 (12): 959-98
18. Anand KJ, Anderson BJ, Holford NH, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 2008; 101 (5): 680-9
19. Bouwmeester NJ, Anderson BJ, Tibboel D, et al. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth 2004; 92 (2): 208-17
20. Saarenmaa E, Neuvonen PJ, Rosenberg P, et al. Morphine clearance and effects in newborn infants in relation to gestational age. Clin Pharmacol Ther 2000; 68 (2): 160-6
21. Scott CS, Riggs KW, Ling EW, et al. Morphine pharmacokinetics and pain assessment in premature newborns. J Pediatr 1999; 135 (4): 423-9
22. Lynn A, Nespeca MK, Bratton SL, et al. Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. Anesth Anals 1998; 86 (5): 958-63
23. Barrett DA, Barker DP, Rutter N, et al. Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. Br J Clin Pharmacol 1996; 41 (6): 531-7
24. Mikkelsen S, Feilberg CL, Christensen CB, et al. Morphine pharmacokinetics in premature andmature newborn infants. Acta Paediatr 1994; 83 (10): 1025-8
25. Hartley R, Green M, QuinnMet al. Pharmacokinetics of morphine infusion in premature neonates. Arch Dis Child 1993; 69 (1): 55-8
26. Pokela ML, Olkkola KT, Seppälä T, et al. Age-related morphine kinetics in infants. Dev Pharmacol Ther 1993; 20 (1-2): 26-34
27. McRorie TI, Lynn AM, Nespeca MK, et al. The maturation of morphine clearance and metabolism. Am J Dis Child 1992; 146 (8): 972-6
28. Choonara I, Lawrence A, Michalkiewicz A, et al. Morphine metabolism in neonates and infants. Br J Clin Pharmacol 1992; 34 (5): 434-7
29. Chay PC, Duffy BJ, Walker JS. Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. Clin Pharmacol Ther 1992; 51 (3): 334-42
30. Choonara I, Ekbom Y, Lindstrom B, et al. Morphine sulphation in children. Br J Clin Pharmacol 1990; 30 (6): 897-900
31. Olkkola KT, Maunuksela EL, Korpela R, et al. Kinetics and dynamics of postoperative intravenous morphine in children. Clin Pharmacol Ther 1988; 44 (2): 128-36
32. Kleiber M. Energy metabolism. Annu Rev Physiol 1944; 6: 123-54
33. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 2006; 165 (12): 819-29
34. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32
35. Coffman BL, King CD, Rios GR, et al. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998; 26 (1): 73-7
36. Ohno S, Kawana K, Nakajin S. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos 2008; 36 (4): 688-94
37. Stone AN, Mackenzie PI, Galetin A, et al. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp- glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 2003; 31 (9): 1086-9
38. Pacifici GM. Pharmacokinetics of antivirals in neonate. Early Hum Dev 2005; 81 (9): 773-80
39. Capparelli EV, Englund JA, Connor JD, et al. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol 2003; 43 (2): 133-40
40. Capparelli EV, Mirochnick M, Dankner WM, et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142 (1): 47-52
41. Osborne R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 34 (2): 130-8
42. Faura CC, Collins SL, Moore RA, et al. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 1998; 74 (1): 43-53
43. Murthy BR, Pollack GM, Brouwer KL. Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J Clin Pharmacol 2002; 42 (5): 569-76
44. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci 1990; 47 (6): 579-85
45. Gong QL, Hedner T, Hedner J, et al. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur J Pharmacol 1991; 193 (1): 47-56